DK1548027T3 - Forbindelse, som bindes til leukocytter, og lægemiddel indeholdende forbindelsen i mærket tilstand som den aktive bestanddel - Google Patents

Forbindelse, som bindes til leukocytter, og lægemiddel indeholdende forbindelsen i mærket tilstand som den aktive bestanddel

Info

Publication number
DK1548027T3
DK1548027T3 DK03798531T DK03798531T DK1548027T3 DK 1548027 T3 DK1548027 T3 DK 1548027T3 DK 03798531 T DK03798531 T DK 03798531T DK 03798531 T DK03798531 T DK 03798531T DK 1548027 T3 DK1548027 T3 DK 1548027T3
Authority
DK
Denmark
Prior art keywords
compound
leukocytes
binding
labeled
image diagnosis
Prior art date
Application number
DK03798531T
Other languages
English (en)
Inventor
I Seki
T Kawaguchi
Y Shirakami
Original Assignee
Nihon Mediphysics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nihon Mediphysics Co Ltd filed Critical Nihon Mediphysics Co Ltd
Application granted granted Critical
Publication of DK1548027T3 publication Critical patent/DK1548027T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Radiology & Medical Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
DK03798531T 2002-09-27 2003-09-26 Forbindelse, som bindes til leukocytter, og lægemiddel indeholdende forbindelsen i mærket tilstand som den aktive bestanddel DK1548027T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002282229 2002-09-27
PCT/JP2003/012362 WO2004029080A1 (ja) 2002-09-27 2003-09-26 白血球結合性化合物およびその標識化合物を有効成分とする医薬組成物

Publications (1)

Publication Number Publication Date
DK1548027T3 true DK1548027T3 (da) 2008-05-13

Family

ID=32040529

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03798531T DK1548027T3 (da) 2002-09-27 2003-09-26 Forbindelse, som bindes til leukocytter, og lægemiddel indeholdende forbindelsen i mærket tilstand som den aktive bestanddel

Country Status (16)

Country Link
US (1) US7220827B2 (da)
EP (1) EP1548027B1 (da)
JP (1) JP4279781B2 (da)
KR (1) KR100900178B1 (da)
CN (1) CN1684973A (da)
AT (1) ATE382632T1 (da)
AU (1) AU2003266655B2 (da)
CA (1) CA2498826A1 (da)
DE (1) DE60318466T2 (da)
DK (1) DK1548027T3 (da)
ES (1) ES2297268T3 (da)
IL (1) IL167518A (da)
NO (1) NO20051948L (da)
NZ (1) NZ538869A (da)
TW (1) TW200418880A (da)
WO (1) WO2004029080A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL158532A0 (en) 2001-05-02 2004-05-12 Purdue Research Foundation Treatment and diagnosis of macrophage mediated disease
TWI332404B (en) * 2004-03-25 2010-11-01 Nihon Mediphysics Co Ltd Medicinal composition containing peptide improved in water solubility and metal labeling efficacy thereof and medicinal formulation containing metal labeled peptide
EP1904183B1 (en) 2005-07-05 2014-10-15 Purdue Research Foundation Pharmaceutical composition for the treatment of osteoarthritis
KR100630489B1 (ko) 2006-01-10 2006-10-04 주식회사 펩트론 면역반응을 조절하는 펩타이드
WO2008098112A2 (en) 2007-02-07 2008-08-14 Purdue Research Foundation Positron emission tomography imaging method
CN101827631B (zh) * 2007-07-11 2013-04-24 得克萨斯系统大学董事会 用于成像中的粒子和标记物
JP6184101B2 (ja) * 2009-12-23 2017-08-23 サンフォード−バーナム メディカル リサーチ インスティテュート アネキシン１結合化合物に関する方法および組成物
CA2772767C (en) 2011-03-30 2019-02-26 Kyoto University Compound accumulating in inflammatory site, diagnostic agent containing the compound in labeled state and its precursor compound for labeling
CN114805598A (zh) * 2019-04-28 2022-07-29 广州市雷德生物科技有限公司 促进蛋白二聚体形成的拉链扣结构及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4986979A (en) 1989-03-14 1991-01-22 Neorx Corporation Imaging tissue sites of inflammation
US5792444A (en) 1989-05-09 1998-08-11 The General Hospital Corporation Labeled chemotactic peptides to image focal sites of infection or inflammation
NZ314680A (en) 1989-05-09 2000-08-25 Ortho Pharma Corp Treating localised infection or inflammation with a therapeutically conjugated chemotactic peptide
EP0814849A1 (en) 1995-10-19 1998-01-07 BRACCO International B.V. Magnetically labeled chemoattractants as targeted contrast agents in the nmr imaging of living tissues
WO2000066622A1 (en) * 1999-05-05 2000-11-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T20/dp178 and t21/dp107 are activators of human phagocyte formyl peptide receptors
AU2754600A (en) * 2000-02-04 2001-08-14 Us Health Ligands for FPR class receptors that induce a host immune response to a pathogen or inhibit HIV infection
US6955884B2 (en) * 2000-10-17 2005-10-18 Trudeau Institute, Inc. Methods for identifying compounds that inhibit CD38 activity

Also Published As

Publication number Publication date
EP1548027A4 (en) 2005-11-16
ATE382632T1 (de) 2008-01-15
CA2498826A1 (en) 2004-04-08
US20060057064A1 (en) 2006-03-16
CN1684973A (zh) 2005-10-19
JP4279781B2 (ja) 2009-06-17
NO20051948L (no) 2005-06-15
EP1548027B1 (en) 2008-01-02
JPWO2004029080A1 (ja) 2006-01-26
US7220827B2 (en) 2007-05-22
DE60318466T2 (de) 2008-09-18
TW200418880A (en) 2004-10-01
DE60318466D1 (de) 2008-02-14
AU2003266655A1 (en) 2004-04-19
EP1548027A1 (en) 2005-06-29
KR20050053691A (ko) 2005-06-08
NZ538869A (en) 2006-09-29
AU2003266655B2 (en) 2009-01-08
KR100900178B1 (ko) 2009-06-02
IL167518A (en) 2009-11-18
WO2004029080A1 (ja) 2004-04-08
ES2297268T3 (es) 2008-05-01

Similar Documents

Publication Publication Date Title
NO20051948L (no) Forbindelser som binder leukocytter og medisinsk sammensetning som inneholder forbindelsen i merket tilstand som aktiv ingrediens
Jamous et al. Synthesis of peptide radiopharmaceuticals for the therapy and diagnosis of tumor diseases
SG152254A1 (en) Contrast agents for myocardial perfusion imaging
NO20064011L (no) Kontrastmidler for myokardial perfusjonsbilleddannelse
IL145535A0 (en) Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases
Serafini From monoclonal antibodies to peptides and molecular recognition units: an overview.
MY133974A (en) Stable reagents for the preparation of radiopharmaceutiocals
WO2008075040A3 (en) Radioactive pet agents for imaging ccr5 in vivo
Hong et al. HaloTag: a novel reporter gene for positron emission tomography
MX2007003518A (es) Agentes formadores de imagenes de inhibidor de metaloproteinasa.
Sakemura et al. Development of a clinically relevant reporter for chimeric antigen receptor T-cell expansion, trafficking, and toxicity
WO2002055111A3 (en) Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
Hall et al. Diagnosis of acute cardiac rejection with antimyosin monoclonal antibody, phosphorous nuclear magnetic resonance imaging, two-dimensional echocardiography, and endocardial biopsy.
MXPA04001113A (es) Formacion de imagenes simultaneas de perfusion cardiaca y agente formador de imagenes dirigido al receptor de vitronectina.
DK0939809T3 (da) TIE-2 receptor-ligand (TIE ligand-4) og dens anvendelse
Nemunaitis et al. Phase I study of recombinant human interleukin-1 beta (rhIL-1 beta) in patients with bone marrow failure.
ITMI20011706A0 (it) Agenti di contrasto radiografici ionici e non ionici, utilizzabili per l'indagine diagnostica combinata tramite raggi-x e risonanza magnetic
WO2002036173A3 (en) Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation
Fletcher Royal Commission: nursing representatives stress quick action on Romanow report
Gholami et al. Intestinal parasite infections in cattle breeders in rural regions of Babol town during 2003
WO2007070827A3 (en) Contrast agents for myocardium perfusion imaging
DE602007007362D1 (de) Radioaktiv markierte verbindungen auf peptidbasis und ihre verwendung
Leung 99mTc-Interleukin-2
Thet Diagnostic significance of Tc-99m tetrofosmin washout for hypertrophic cardiomyopathy: clinical and basic investigation
Saphir Ruling may not help hospitals in long term.